RELAPSED CANCER

This study is testing a new oral drug called BGB-16673, which breaks down a protein that helps cancer cells grow, in combination with other cancer drugs. It is for people with B-cell cancers (like certain lymphomas) that have come back or stopped responding to treatment. The tria…

This study tests a new combination of three drugs—roginolisib, venetoclax, and rituximab—in people with chronic lymphocytic leukemia (CLL) that has come back or not responded to prior treatments. The goal is to see if the combination is safe and can wipe out leukemia cells more e…

This study tests a combination of three drugs—pembrolizumab, ibrutinib, and rituximab—in people whose primary central nervous system lymphoma has come back or not responded to prior treatment. The goal is to see if the combo can stop the cancer from growing for at least 6 months.…

This study tests whether teclistamab, a drug for relapsed or refractory multiple myeloma, can be given safely outside the hospital. It involves 15 patients who have tried at least 3 prior treatments. The goal is to develop a clear process for outpatient care and measure how this …

This study tests a combination of two drugs, zanubrutinib and pemetrexed, followed by zanubrutinib alone, in people whose central nervous system lymphoma has returned or stopped responding to treatment. The goal is to see if this approach can shrink tumors and control the disease…

This study tests a combination of the immunotherapy drug epcoritamab with standard chemotherapy (GDP) in 32 adults whose large B-cell lymphoma has returned or not responded to treatment. The goal is to see if the combo can shrink tumors enough to allow for a stem cell transplant …